Metabolismo De Lipideos !!hot!! May 2026

Lipid metabolism is exquisitely controlled by hormonal and nutritional signals. Insulin promotes anabolism (lipogenesis, TAG storage) and suppresses catabolism (inhibits HSL, activates ACC). Glucagon and epinephrine do the opposite, activating lipolysis and β-oxidation. The AMPK (AMP-activated protein kinase) system acts as a cellular fuel gauge: low energy (high AMP) activates AMPK, which shuts down energy-consuming anabolic pathways (e.g., ACC, HMG-CoA reductase) and turns on catabolic ones (e.g., fatty acid uptake and oxidation).

Introduction

The journey of dietary lipids begins in the gastrointestinal tract. The hydrophobic nature of triglycerides (TAGs), phospholipids, and cholesterol esters necessitates emulsification by bile salts in the small intestine. Pancreatic lipase, along with its cofactor colipase, then cleaves TAGs into free fatty acids (FFAs) and 2-monoacylglycerols. Phospholipase A2 acts on phospholipids, while cholesterol esterase hydrolyzes cholesterol esters. These breakdown products are incorporated into mixed micelles, which diffuse to the enterocyte brush border for absorption. metabolismo de lipideos

These newly synthesized fatty acids are esterified to glycerol-3-phosphate to form TAGs for storage. They are also incorporated into membrane phospholipids via the Kennedy pathway or by remodeling existing phospholipids (Lands’ cycle). Cholesterol synthesis (isoprenoid pathway) is another critical anabolic component, beginning with HMG-CoA reductase—the target of statin drugs. Cholesterol is essential for membrane fluidity, lipid rafts, and steroid hormone synthesis. The coordinated regulation of lipogenesis, TAG assembly, and cholesterol synthesis by insulin, SREBP (sterol regulatory element-binding proteins), and ChREBP (carbohydrate response element-binding protein) ensures that excess carbon is stored efficiently. Lipid metabolism is exquisitely controlled by hormonal and

In conclusion, the metabolismo de lípidos is not a simple tale of fat storage and fuel use. It is an elegantly integrated system of digestion, transport, mitochondrial oxidation, ketone body production, and cytosolic synthesis of fatty acids and cholesterol. These pathways are dynamically tuned by hormonal signals (insulin, glucagon) and energy sensors (AMPK) to maintain metabolic homeostasis. From providing sustained energy during a marathon to building the phospholipid bilayers that define cellular life, from synthesizing steroid hormones to the pathological consequences of their dysregulation—lipid metabolism lies at the very core of human physiology and disease. A deep, mechanistic understanding of these processes is indispensable for developing rational therapies against the modern epidemics of metabolic syndrome and cardiovascular disease. Future research continues to uncover the nuances of lipid signaling, organelle crosstalk, and tissue-specific regulation, promising new targets for therapeutic intervention. The AMPK (AMP-activated protein kinase) system acts as

Inside the cell, FFAs are activated to fatty acyl-CoA by acyl-CoA synthetase. The critical entry step into the mitochondria, where β-oxidation occurs, is mediated by the carnitine shuttle. The enzyme carnitine palmitoyltransferase I (CPT1) is the rate-limiting, regulated step; it converts fatty acyl-CoA to acylcarnitine, which is transported across the inner mitochondrial membrane by translocase and then reconverted to acyl-CoA by CPT2. Malonyl-CoA, the first intermediate in fatty acid synthesis, allosterically inhibits CPT1—a prime example of reciprocal regulation between catabolism and anabolism.

Dysregulation of these pathways underlies major diseases. results from chronic positive energy balance, with hypertrophied adipocytes becoming insulin-resistant and releasing excess FFAs (lipotoxicity). Atherosclerosis is driven by retention of apoB-containing lipoproteins (LDL) in artery walls, where they become oxidized, triggering inflammation and plaque formation. NAFLD arises from ectopic TAG accumulation in the liver due to increased lipogenesis and reduced VLDL export, often in the context of insulin resistance. The carnitine shuttle defects cause hypoketotic hypoglycemia and cardiomyopathy in infants. Understanding these pathways has led to effective therapies: statins (HMG-CoA reductase inhibitors), fibrates (PPAR-α activators that enhance fatty acid oxidation), and emerging inhibitors of ACC or SCD1 for NAFLD.